Infection By Onchocerca Volvulus — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for infection by onchocerca volvulus. 5 active patents protecting 1 drugs from 1+ originators. First major cliff: 2034. Daily refresh.

1
Approved drugs
5
Active US patents
62/100
Avg vulnerability
—
Annual revenue covered

Originators in Infection By Onchocerca Volvulus

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Merck & Co. 5 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating infection by onchocerca volvulus. Each bar = one year. Y-axis scaled to peak year (5 patents).

5
34

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Stromectol
ivermectin
 Merck & Co. 5 62 — 2034-03-13

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
10206939 Stromectol method of use 62 2034-03-13
9233117 Stromectol method of use 62 2034-03-13
9233118 Stromectol method of use 62 2034-03-13
9089587 Stromectol method of use 62 2034-03-13
9782425 Stromectol method of use 62 2034-03-13

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10206939 Stromectol method of use 62 2034-03-13
9233117 Stromectol method of use 62 2034-03-13
9233118 Stromectol method of use 62 2034-03-13
9089587 Stromectol method of use 62 2034-03-13
9782425 Stromectol method of use 62 2034-03-13

Related